# Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer

> **NCT04624399** · PHASE2 · RECRUITING · sponsor: **Queen Mary University of London** · enrollment: 58 (estimated)

## Conditions studied

- Urogenital Cancer

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04624399
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-17
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-05-30
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04624399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04624399, "Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04624399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*